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ABSTRACT
Objective: To estimate the attributable and targeted
avoidable deaths (ADs; TADs) of outdoor air pollution by
ambient particulate matter (PM10), PM2.5 and O3
according to specific WHO methodology.
Design: Health impact assessment.
Setting: City of Valladolid, Spain (around 300 000
residents).
Data sources: Demographics; mortality; pollutant
concentrations collected 1999–2008.
Main outcome measures: Attributable fractions; ADs
and TADs per year for 1999–2008.
Results: Higher TADs estimates (shown here) were
obtained when assuming as ‘target’ concentrations WHO
Air Quality Guidelines instead of Directive 2008/50/EC.
ADs are considered relative to pollutant background
levels. All-cause mortality associated to PM10 (all ages):
52 ADs (95% CI 39 to 64); 31 TADs (95% CI 24 to 39).
All-cause mortality associated to PM10 (<5 years): 0 ADs
(95% CI 0 to 1); 0 TADs (95% CI 0 to 1). All-cause
mortality associated to PM2.5 (>30 years): 326 ADs
(95% CI 217 to 422); 231 TADs (95% CI 153 to 301).
Cardiopulmonary and lung cancer mortality associated to
PM2.5 (>30 years):
▸ Cardiopulmonary: 186 ADs (95% CI 74 to 280);
94 TADs (95% CI 36 to 148).
▸ Lung cancer : 51 ADs (95% CI 21 to 73); 27 TADs
(95% CI 10 to 41).All-cause, respiratory and
cardiovascular mortality associated to O3 (all ages):
▸ All-cause: 52ADs (95% CI 25 to 77) ; 31 TADs (95%
CI 15 to 45).
▸ Respiratory: 5ADs (95% CI −2 to 13) ; 3 TADs (95%
CI −1 to 8).
▸ Cardiovascular: 30 ADs (95% CI 8 to 51) ; 17 TADs
(95% CI 5 to 30).
Negative estimates which should be read as zero were
obtained when pollutant concentrations were below
counterfactuals or assumed risk coefficients were below
one.
Conclusions: Our estimates suggest a not negligible
negative impact on mortality of outdoor air pollution. The
implementation of WHO methodology provides critical
information to distinguish an improvement range in air
pollution control.
INTRODUCTION
Numerous epidemiological studies con-
ducted over the past decades point to
adverse health impacts from exposure to
outdoor air pollution, attributing the most
severe health effects to particulate matter
(PM)1 2 and, to a lesser extent, ozone3 (O3).
New studies incorporate to the growing body
of evidence,4–6 currently under review by the
WHO through projects such as REVIHAAP
(Review of evidence on health aspects of air
pollution) and HRAPIE (Health risks of air
pollution in Europe), conﬁrming that
outdoor air pollution is an important risk
factor for health.7 8
According to the WHO, in the year 2012,
ambient air pollution was responsible for 3.7
million deaths, representing 6.7% of the
total deaths. Worldwide, ambient air pollu-
tion is estimated to cause about 16% of the
lung cancer deaths, 11% of chronic obstruct-
ive pulmonary disease deaths, more than
20% of ischaemic heart disease and stroke,
and about 13% of respiratory infection
deaths.9 Recently, the International Research
Agency on Cancer (IARC) classiﬁed air pol-
lution mixture and PM as carcinogenic to
human beings (Group 1).10
It could be expected that the impact caused
by a preventable risk factor would decline if
the exposure to that risk factor could be
Strengths and limitations of this study
▪ Using ecological data to assume ambient pollu-
tant concentrations as surrogates of individual
exposure adds error.
▪ In addition, pollutant concentrations were not
corrected for sub-Saharan dust intrusions.
▪ CIs only cover statistical uncertainty related to
the risk estimates from the concentration-
response functions (CRFs), currently under
review by the WHO, while further uncertainty is
added due to potential errors in assuming the
general shape of CRFs, background pollutant
levels, selection of health outcomes and struc-
ture of monitoring network.
▪ In sensitivity analysis, we considered different
PM2.5/PM10 ratios, background concentrations
and exposure-response relationships.
▪ It is difficult to generalise results to other popu-
lations as data were obtained from only one city.
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reduced or removed. According to this approach, the pro-
portional reduction in the number of health problems or
deaths as a result of reducing the risk factor is known as
the attributable fraction (AF).11
Estimating the environmental burden of disease asso-
ciated with exposure to air pollution is critical informa-
tion for policymakers who can deﬁne strategies and
prioritise actions by considering the health gains that
could be achieved if the exposure to the risk factor were
reduced to a ‘target’ concentration.1
We estimated the burden of mortality from exposure
to PM10, PM2.5 and O3 at the city of Valladolid, as a
health impact assessment (HIA) under various exposure
scenarios in order to provide quantitative information of
the potential beneﬁts of reducing the exposure to these
pollutants.
METHODS
Calculation of burden of mortality
On the basis of the method outlined by the WHO in the
Environmental Burden of Disease (EBD) series1 12 we
followed a classical risk assessment approach:
1. Determination of the ambient exposure of the popu-
lation using data from model estimates or monitoring
networks. A ‘counterfactual’ background or target
concentration is also needed to determine the attrib-
utable disease or the potential gains of a reduction
strategy.
2. Number of people exposed to air pollutants.
3. Baseline incidence of the adverse health outcomes
associated with air pollutants (eg, the mortality rate
in the population).
4. Concentration-response functions (CRFs) that relate
changes in air pollutants concentrations with changes
in the incidence of adverse health effects.
Assessment of the ambient exposure of the population
About 300 000 people live in Valladolid, a Spanish city
located at an altitude of 698 m in the Inner Plateau,
200 km North to Madrid. The orography of this plateau
surrounded by mountains except on the border with
Portugal favours winds penetrating from the Atlantic
Ocean and on the contrary prevents or greatly reduces
air circulation to and from the Bay of Biscay and the
Southern Plateau. Notably, the Central System Range iso-
lates Valladolid from the inﬂuence of Madrid as a great
source of precursors, at least respecting direct transport
at surface level. The climate is continental, with cold
winters and dry summers. The pollution levels are
strongly dependent on the atmospheric synoptic condi-
tions, in this case a long and cold winter, with frequent
fog events. The type of surface that surrounds the city is
basically rough, bare and dry soil used primarily for agri-
culture. The urban aerosol corresponds to a lightly
industrialised city whose contamination mostly comes
from road trafﬁc and domestic heating. Regarding eco-
nomic activity, automotive sector is an important
manufacturing industry. As natural sources of PM affect-
ing occasionally the area, wildﬁres and wind-blown dust-
like Saharan intrusions can be included. Regarding
ozone, orography and solar radiation favour ozone for-
mation and accumulation. No municipal emission
source inventory has been developed yet.13–15
PM10 concentrations (annual means) were obtained
from the annual reports 1999–2008 published by the
Environmental Health Unit (EHU) of the city council
responsible for the municipal ﬁxed-site monitoring sta-
tions network.16 O3 concentrations (daily maximum 8 h
means) were provided on request to the EHU.The
annual mean concentrations from the operating stations
with a minimum data capture of 90% (operating stations
with valid data according to regulatory standards)17–19
for the 10 years of data 1999–2008 were averaged to
develop the following annual average estimates for PM10
and O3: 35.41 and 141.38 μg/m
3, respectively. As there
were no direct measures of PM2.5, they were estimated
by applying the recommended PM2.5/PM10 ratio of 0.73
for Europe.1 Hence, the estimated concentration for
PM2.5 was 25.85 μg/m
3. Table 1 provides a scope of our
exposure data set.
Population exposed and mortality data
Annual population ﬁgures from the municipal register
and annual deaths by different causes and age groups
(underlying causes of death selected according to
WHO1 8 20 and coded in accordance with the
International Classiﬁcation of Diseases (ICD) 10th
version), extracted from the Spanish Statistical Ofﬁce for
1999–2008,21 were averaged and rounded off to the
nearest whole number to obtain population and mortality
ﬁgures for different age groups. In doing so, respiratory
mortality for children <5 years old resulted zero. Crude
mortality rates (in deaths per 100 000 people) for each
age group and health outcomes were calculated. Table 2
describes population indicators and mortality rates by age
group for the period of analysis.
Concentration-response functions
Epidemiological studies can use regression models that
generate relative risk (RR) functions with a β-coefﬁcient
that relates the per cent change in the health outcome
to a unit change in air pollutant concentration, that is,
an increase of the risk per 10 μg/m3 PM10. CRFs are
equations derived from epidemiological studies that link
the change in the number of adverse health effect inci-
dences in a population to a change in pollutant concen-
tration experienced by that population. Existing studies
have reported either a β-coefﬁcient or a RR.
Additionally, 95% CIs are provided for the β-coefﬁcients
and RR estimates in order to obtain upper and lower
bounds of the health impacts.1 8 20
According to the WHO and depending on data avail-
ability, we used the recommended and alternative risk
functions summarised in table 3 to calculate the RR for
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the following mortality outcomes associated with expos-
ure to PM10, PM2.5 and O3.
1 8 20 As not all of the listed
outcomes can be reliably converted into DALYs
(disability-adjusted life years) estimates and owing to
data availability, preference was given to mortality
instead of morbidity indicators or DALYs estimates as
the health effect for this assessment. Short-term esti-
mates should not be added to long-term estimates or
estimates for children, since that would involve some
double counting of the mortality cases.1
1. All-cause (natural) mortality associated with short-
term exposure to PM10 for all ages.
1 These results
should not be added to the other mortality estimates.
DALYs cannot be determined for each of these pre-
mature deaths but can be used as an alternative to
DALYs, and used as a basis for comparing short-term
and long-term effects of pollutant exposure.1
2. All-cause (natural) and respiratory mortality in
infants and children <5 years old related to short-
term exposure to PM10.
1 The application of this rate
Table 1 PM10 and O3 concentration data set
Pollutant Year
Number of
operating stations
Operating stations
with valid data Minimum Maximum Annual average SD
PM10 1999 7 2 44 47 45.5 2.121
2000 7 7 33 47 41.6 5.127
2001 7 4 38 46 42.7 3.695
2002 8 4 25 39 33.3 5.909
2003 6 6 23 39 30.2 6.853
2004 6 4 33 52 39.5 8.583
2005 6 6 31 49 36.2 6.911
2006 6 5 30 41 36.4 4.393
2007 5 5 20 31 25.6 4.159
2008 6 4 22 26 23.3 1.893
O3 1999 4 4 89 134 111.5 19.638
2000 4 4 101 152 121.3 21.930
2001 4 2 122 130 126 5.657
2002* 3 1 126 168.7 147.3 30.169
2003 4 3 165 174 168.7 4.726
2004 3 3 142 164 149.7 12.423
2005 3 3 146 159 154.7 7.506
2006 3 3 138 151 142.7 7.234
2007 3 3 137 146 143 5.196
2008 3 3 138 160 149 11
*In 2002 1 of 3 stations could provide valid data so it was decided to use the average of the years 2001 and 2003.
PM, particulate matter.
Table 2 Population data and cause-specific mortality by age group (1999–2008)
All ages
Population All-cause (natural) mortality Respiratory mortality Cardiovascular mortality
319.482 2.563 267 872
Mortality rate*
802 83 273
>30 years
Population All-cause (natural) mortality Cardiopulmonary mortality Lung cancer mortality
212.702 2.535 729 142
Mortality rate*
1.192 342 67
<5 years
Population All-cause (natural) mortality Respiratory mortality†
11.752 12 0
Mortality rate*
100 2
International Classification of Diseases 10th version: all-cause (natural) mortality: all except V01-Y89; respiratory mortality: J00-J99;
cardiovascular mortality: I00-I99; cardiopulmonary mortality: I00-I02; I10-I15; I20-I49; I51-I52; J00-J99; lung cancer mortality: C33-C34.
*Mortality rate in deaths per 100 000 people.
†There were two cases of death of respiratory mortality for children <5 years in 2003 (period 1999–2008). The annual average of respiratory
mortality for 1999–2008, rounded off to the nearest whole number, resulted 0. Hence, the respiratory mortality rate per 100 000 people is 2.
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Table 3 Health outcomes and risk functions used to calculate the burden of disease associated to PM10, PM2.5 and O3
Outcome and exposure metric RR function*
β-coefficient/RR
(95% CI) Age group ICD-10 codes
All-cause (natural) mortality and short-term exposure to PM10 RR=exp [β (X−Xo)] 0.00081
(0.0006 to 0.0010)
All ages All except V01-Y89
All-cause (natural) and respiratory mortality and short-term exposure to PM10† RR=exp [β (X−Xo)] 0.00 1661
(0.00 034 to 0.0030)
<5 years All except V01-Y89/
J00-J99‡
All cause (natural) mortality and long-term exposure to PM2.5 RR=exp [β (X−Xo)] 1.0628
(1.040 to 1.083)
>30years All except V01-Y89
Cardiopulmonary mortality and long-term exposure to PM2.5 (log-linear exposure)§ RR=[(X+1)/(Xo)+1)]
β 0.15 5151
(0.0562 to 0.2541)
>30 years I00-I02 ;I10-I15 ;I20-I49
;I51-I52 ;J00-J99
Cardiopulmonary mortality and long-term exposure to PM2.5 (linear exposure) RR=exp [β (X−Xo)] 0.00 8931
(0.00 322–0.01 464)
>30 years I00-I02 ;I10-I15 ;I20-I49
;I51-I52 ;J00-J99
Lung cancer and long-term exposure to PM2.5 (log-linear exposure)§ RR=[(X+1)/(Xo)+1)]
β 0.23 2181
(0.08 563 to 0.37 873)
>30 years C33-C34
Lung cancer and long-term exposure to PM2.5 (linear exposure) RR=exp [β (X−Xo)] 0.01 2671
(0.00 432 to 0.02 102)
>30 years C33-C34
All-cause mortality and short-term exposure to O3 RR=exp [β (X−Xo)] 1.00220
(1.0005 to 1.0035)
1.00298
(1.0014 to 1.0043)
All ages All except V01-Y89
Respiratory mortality and short-term exposure to O3 RR=exp [β (X−Xo)] 0.99920
(0.995 to 1.004)
1.00298
(0.9989 to 1.0070)
All ages J00-J99
Cardiovascular mortality and short-term exposure to O3 RR=exp [β (X−Xo)] 1. 00420
(1.003 to 1.005)
1.00498
(1.0013 to 1.0085)
All ages I00-I99
*X=current pollutant concentration (μg/m3) and Xo=target or threshold pollutant concentration (μg/m
3).
†All-cause mortality for upper bound where applicable.
‡Respiratory mortality.
§Recommended relationship.
ICD-10 codes, International Classification of Diseases 10th version; PM, particulate matter; RR, relative risk.
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to all-cause mortality could however represent an
upper boundary of disease burden caused by
outdoor air pollution, but may result in an overesti-
mate when applied to certain regions.1
3. All-cause (natural) mortality associated with long-
term exposure to PM2.5 for >30 years old.
8 The
recommended risk coefﬁcient is based on the
meta-analysis of cohort studies published by Hoek
et al4 According to the HRAPIE report (2013), prefer-
ence was given to use of the all-cause function
instead of cause-speciﬁc indicators.8
4. Cardiopulmonary and lung cancer mortality related to
long-term exposure to PM2.5 for >30 years old.
1 The
long-term estimate should not be added to the estimate
for short-term exposure, since this would double count
a portion, if not all, of the short-term cases.1
5. All-cause (natural), respiratory and cardiovascular
mortality related to short-term exposure to O3 for all
ages.8 20 Using two different sets of risk coefﬁcients
estimates for the same outcomes (from Anderson
et al and the HRAPIE report, 2013) enabled the
results under these assumptions to be compared. The
coefﬁcients summarised by Anderson et al20 were
revised for publication bias.
Examining the sensitivity of the results to alternative
assumptions is recommended.1 A sensitivity analysis
was conducted using alternative values for these
parameters:
▸ PM2.5/PM10 ratio: an alternative ratio of 0.65
1 8 that
results in an estimated PM2.5 concentration of
23.01 µg/m3 was examined. This ratio is considered
an average for the European population by the
HRAPIE report. However, in speciﬁc locations the
ratio may be in the range 0.4–0.8.8
▸ Background concentrations for PM2.5 and O3
1 3 22:
7.5 and 50 µg/m3, respectively.
▸ Shape of the CRF: for cardiopulmonary and lung
cancer mortality associated with PM2.5 exposure a
linear model was examined as an alternative to the
recommended log-linear relationship.1
Those RR functions in table 3 compare current mea-
sured pollutant concentrations with a counterfactual level
(a hypothetical ‘natural’ background or a ‘target’ concen-
tration). Therefore, two kinds of calculations can be
made1:
1. The total number of attributable deaths (ADs) due
to current air pollution levels.
2. The number of deaths that could be prevented if the
target concentration were achieved (targeted avoid-
able deaths, TADs).
The only difference between the two calculations is
the counterfactual level used in (1) it is the ‘natural’
background level (ie, the level that would exist without
any man-made pollution) and (2) it is a ‘target’ concen-
tration.1 Different counterfactual concentrations were
selected to reﬂect different exposure scenarios, as
described following.
The counterfactual concentrations used for PM10 were:
▸ 10 µg/m3: background level scenario.1
▸ 20 µg/m3: target value scenario from the WHO Air
Quality Guidelines (AQG).23
▸ 40 µg/m3: target value scenario from the Directive
2008/50/EC.19
Four counterfactual concentrations were used for PM2.5:
▸ 3 µg/m3: background level scenario.1
▸ 10 µg/m3: target value scenario from the WHO AQG.23
▸ 25 µg/m3: target value scenario from the Directive
2008/50/EC.19
▸ 7.5 µg/m3: alternative background level for sensitivity
analysis.1 22
Four counterfactual concentrations were used for O3:
▸ 70 µg/m3: background level scenario from the WHO
AQG.23
▸ 100 µg/m3: target value scenario from the WHO
AQG.23
▸ 120 µg/m3: target value scenario from the Directive
2008/50/EC.19
▸ 50 µg/m3: alternative background level for sensitivity
analysis.3
Once the RRs have been computed, the AF is deter-
mined in the classic attributable risk calculation1:
AF ¼ (RR  1)=RR
Regarding O3 exposure, these RR estimates can be con-
verted into an estimated β using the following equation
where ΔO3 is a speciﬁed change in pollutant (ie, for a
10 μg/m3 increase)24:
b ¼ Ln(RR)=DO3
Then, the difference between current ozone (8 h mean)
and a counterfactual level is used to calculate RR as
follows24:
RR ¼ exp(bDO3)
These RR estimates are subsequently applied to deter-
mine the AF as stated before. Ultimately, the expected
number of deaths is calculated by1:
E ¼ AFM P
where M, mortality rate; P, exposed population size.
The previous steps come with a range of assumptions
and uncertainties. To reﬂect these uncertainties results
are presented with a point estimate as well as an upper
and lower bound given by the 95% CI of the CRF.ADs
and TADs estimates were rounded off to the nearest
whole number.
RESULTS
Table 4 shows the impact (in terms of mortality) of the
estimated current ambient levels of pollutants relative to
the assumed background concentrations and the beneﬁt
of reducing pollutant concentrations to the levels set as
targets by the WHO AQG or the Directive 2008/50/EC.
Our estimates point out that compliance with the WHO
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AQG target values might result in higher savings, in
terms of mortality avoided, than with the Directive
2008/50/EC standards. Morbidity adverse health effects
are not included in the assessment.
This table presents the annual number of ADs and
TADs (deaths per year) for the period 1999–2008 along
with their corresponding AFs (multiplied by 100 to
express as percentage).
Table 4 Annual number of deaths (deaths per year) from outdoor air pollution for 1999–2008
All-cause mortality and short-term exposure to PM10: all ages
1
Counterfactual concentration *20 µg/m3 †40 µg/m3 ‡10 µg/m3
Indicator AFs TADs AFs TADs AFs ADs
Lower estimate 0.92 24 −0.276 −7 1.513 39
Central estimate 1.225 31 −0.368 −9 2.012 52
Higher estimate 1.529 39 −0.46 −12 2.509 64
All-cause mortality and short-term exposure to PM10: age <5 years*
Counterfactual concentration †20 µg/m3 ‡40 µg/m3 ‡10 µg/m3
Indicator AFs TADs AFs TADs AFs ADs
Lower estimate 0.523 0 −0.156 0 0.86 0
Central estimate 2.526 0 −0.765 0 4.13 0
Higher estimate 4.518 1 −1.386 0 7.34 1
All-cause mortality and long-term exposure to PM2.5: age >30 years
8
Counterfactual concentration *10 µg/m3 †25 µg/m3 ‡3 µg/m3
Indicator AFs TADs AFs TADs AFs ADs
Lower estimate 6.027 153 0.333 8 8.572 217
Central estimate 9.094 231 0.510 13 12.842 326
Higher estimate 11.872 301 0.675 17 16.656 422
Cardiopulmonary mortality and long-term exposure to PM2.5: age >30 years
1
Counterfactual concentration *10 µg/m3 †25 µg/m3 ‡3 µg/m3
Indicator AFs TADs AFs TADs AFs ADs
Lower estimate 4.891 36 0.181 1 10.148 74
Central estimate 12.929 94 0.498 4 25.577 186
Higher estimate 20.288 148 0.814 6 38.356 280
Lung cancer mortality and long-term exposure to PM2.5: age >30 years
1
Counterfactual concentration *10 µg/m3 †25 µg/m3 ‡3 µg/m3
Indicator AFs TADs AFs TADs AFs ADs
Lower estimate 7. 357 10 0.275 0 15.044 21
Central estimate 18.713 27 0.744 1 35.729 51
Higher estimate 28.678 41 1.211 2 51.378 73
All-cause mortality and short-term exposure to O3: all ages
Counterfactual concentration *100 µg/m3 †120 µg/m3 §70 µg/m3
Indicator AFs TADs AFs TADs AFs ADs
Source of risk estimates: Anderson et al 20
Lower estimate 0.207 5 0.107 3 0.356 9
Central estimate 0.823 21 0.426 11 1.416 36
Higher estimate 1.435 37 0.744 19 2.463 63
Source of risk estimates: HRAPIE Project 8
Lower estimate 0.577 15 0.299 8 0.994 25
Central estimate 1.191 31 0.617 16 2.046 52
Higher estimate 1.760 45 0.913 23 3.016 77
Respiratory mortality and short-term exposure to O3: all ages
Counterfactual concentration *100 µg/m3 †120 µg/m3 §70 µg/m3
Indicator AFs TADs AFs TADs AFs ADs
Source of risk estimates: Anderson et al 20
Lower estimate −2.096 −6 −1.077 −3 −3.642 −10
Central estimate −0.415 −1 −0.214 −1 −0.717 −2
Higher estimate 1.638 4 0.85 2 2.809 7
Continued
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As for the TADs, which estimate the number of deaths
that could have been avoided in case of having reduced
the air pollutant concentrations to the levels set as a
target, the AFs estimate the proportional reduction of
the mortality cause that could have been prevented in
case of having decreased to the target scenario the
exposure to the air pollutant. Regarding the ADs, which
estimate the number of deaths due to current air pollu-
tion concentrations relative to the assumed background
levels, the AFs estimate the proportion of the mortality
cause that could have been attributed to those
pollutants.
ADs and TADs estimates were rounded off to the
nearest whole number. For this reason, zero values for
ADs and TADs are calculated for all-cause mortality
related to PM10 for <5 years and for lung cancer mortal-
ity related to PM2.5 in >30 years under the Directive
2008/50/EC exposure scenario (25 µg/m3). Negative
estimates, which should be read as zero, were obtained
when current pollutant concentrations were below the
counterfactual value assumed (Directive 2008/50/EC
exposure scenario for all-cause mortality related to
exposure to PM10) or assumed risk coefﬁcients were
below 1 (for respiratory mortality related to exposure to
O3: the lower and central risk estimates revised for publi-
cation bias from Anderson et al and the lower risk esti-
mate from HRAPIE project). Likewise, since annual
average for 1999–2008 of respiratory mortality for chil-
dren <5 years old was rounded off to zero, ADs and
TADs estimates for respiratory mortality related to PM10
exposure for this age group resulted null and are not
presented. It bears noting that AFs of respiratory mortal-
ity for children <5 years are the same as for all-cause
mortality.
When applying the more stringent WHO target values
scenarios, higher TADs and AFs estimates than under
Directive 2008/50/EC exposure conditions were
obtained. Overall, estimates for the mortality related to
PM2.5 exposure were higher than for PM10 and O3.
Speciﬁcally, for cardiopulmonary and lung cancer mor-
tality associated to PM2.5 exposure, notable AFs were
obtained and the CIs show quite a broader range than
those for mortality related to PM10 and O3.
Concerning mortality associated to O3 exposure,
central and higher estimates were slightly larger when
assuming the risk coefﬁcients derived from the HRAPIE
project than those from Anderson et al. For respiratory
mortality, negative estimates were obtained as described
previously. CIs range is narrower than for mortality esti-
mates associated to PM2.5. The overall picture from the
two sets of coefﬁcients assumed might be considered
similar.
Table 5 provides the estimates for the different input
parameters evaluated as a sensitivity analysis.
Overall, for long-term effects of PM2.5 exposure, the
results remained within the range calculated on the
basis of the recommended parameters. For the alterna-
tive PM2.5/PM10 ratio of 0.65, negative TADs estimates
were obtained as the counterfactual level of 25 µg/m3
(Directive 2008/50/EC) was higher than the estimated
PM2.5 concentration of 23.01 µg/m
3 for the alternative
ratio. Broadly, estimates under the recommended ratio
Table 4 Continued
Respiratory mortality and short-term exposure to O3: all ages
Counterfactual concentration *100 µg/m3 †120 µg/m3 §70 µg/m3
Source of risk estimates: HRAPIE Project 8
Lower estimate −0.456 −1 −0.236 −1 −0.789 −2
Central estimate 1.191 3 0.617 2 2.046 5
Higher estimate 2.845 8 1.480 4 4.857 13
Cardiovascular mortality and short-term exposure to O3: all ages
Counterfactual concentration *100 µg/m3 †120 µg/m3 §70 µg/m3
Indicator AFs TADs AFs TADs AFs ADs
Source of risk estimates: Anderson et al 20
Lower estimate 1.232 11 0.638 6 2.115 18
Central estimate 1.638 14 0.85 7 2.809 25
Higher estimate 2.042 18 1.06 9 3.497 31
Source of risk estimates: HRAPIE Project 8
Lower estimate 0.536 5 0.277 2 0.923 8
Central estimate 2.002 17 1.039 9 3.429 30
Higher estimate 3.441 30 1.793 16 5.862 51
Counterfactual concentrations:
*Target concentration from WHO.23
†Target concentration from Directive 2008/50/EC.19
‡Background level from Ostro.1
§Background level from WHO.23
ADs, attributable deaths; AFs, attributable fractions; HRAPIE, Health risks of air pollution in Europe; PM, particulate matter; TADs, targeted
avoidable deaths.
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Table 5 Effects of alternative assumptions on annual number of deaths estimates (deaths per year)
All-cause mortality and long-term exposure to PM2.5: age >30 years
8
PM2.5/PM10 ratio: 0.73
1
Counterfactual concentration *10 µg/m3 †25 µg/m3 ‡3 µg/m3 ‡§7.5 µg/m3
Indicator AFs TADs AFs TADs AFs ADs AFs ADs
Lower estimate 6.027 153 0.333 8 8.572 217 6.944 176
Central estimate 9.094 231 0.510 13 12.842 326 10.451 265
Higher estimate 11.872 301 0.675 17 16.656 422 13.611 345
PM2.5/PM10 ratio: 0.65
1 8
Lower estimate 4.977 126 −0.781 −20 7.551 191 5.904 150
Central estimate 7.532 191 −1.200 −30 11.344 288 8.912 226
Higher estimate 9.859 250 −1.594 −40 14.752 374 11.638 295
Cardiopulmonary mortality and long-term exposure to PM2.5: age >30 years
1
Log-linear relationship1
PM2.5/PM10 ratio: 0.73
1
Counterfactual concentration *10 µg/m3 †25 g/m3 ‡3 µg/m3 ‡§7.5 µg/m3
Indicator AFs TADs AFs TADs AFs ADs AFs ADs
Lower estimate 4.891 36 0.181 1 10.148 74 6.26 46
Central estimate 12.929 94 0.498 4 25.577 186 16.344 119
Higher estimate 20.288 148 0.814 6 38.356 280 25.343 185
PM2.5/PM10 ratio: 0.65
1 8
Lower estimate 4.294 31 −0.447 −3 9.583 70 5.670 41
Central estimate 11.410 83 −1.238 −9 24.278 177 14.884 109
Higher estimate 17.997 131 −2.036 −15 36.585 267 23.198 169
Linear relationship1
PM2.5/PM10 ratio: 0.73
1
Counterfactual concentration *10 µg/m3 †25 µg/m3 ‡3 µg/m3 ‡§7.5 µg/m3
Indicator AFs TADs AFs TADs AFs ADs AFs ADs
Lower estimate 4.976 36 0.273 2 7.094 52 5.738 42
Central estimate 13.198 96 0.756 6 18.458 135 15.114 110
Higher estimate 20.709 151 1.237 9 28.432 207 23.558 172
PM2.5/PM10 ratio: 0.65
1 8
Lower estimate 4.105 30 −0.641 −5 6.242 46 4.874 36
Central estimate 10.974 80 −1.786 −13 16.369 119 12.940 94
Higher estimate 17.351 126 −2.945 −21 25.402 185 20.322 148
Lung cancer mortality and long-term exposure to PM2.5: age >30 years
1
Log-linear relationship1
PM2.5/PM10 ratio: 0.73
1
Counterfactual concentration *10 µg/m3 †25 µg/m3 ‡3 µg/m3 ‡§7.5 µg/m3
Indicator AFs TADs AFs TADs AFs ADs AFs ADs
Lower estimate 7.357 10 0.275 0 15.044 21 9.38 13
Central estimate 18.713 27 0.744 1 35.729 51 23.437 33
Higher estimate 28.678 41 1.211 2 51.378 73 35.313 50
PM2.5/PM10 ratio: 0.65
1 8
Lower estimate 6.468 9 −0.682 −1 14.229 20 8.510 12
Central estimate 16.582 24 −1.859 −3 34.044 48 21.429 30
Higher estimate 25.602 36 −3.050 −4 49.281 70 32.523 46
Linear relationship1
PM2.5/PM10 ratio: 0.73
1
Counterfactual concentration *10 µg/m3 †25 µg/m3 ‡3 µg/m3 ‡§7.5 µg/m3
Indicator AFs TADs AFs TADs AFs ADs AFs ADs
Lower estimate 6.618 9 0.367 1 9.4 13 7.621 11
Central estimate 18.194 26 1.071 2 25.137 36 20.745 29
Higher estimate 28.335 40 1.771 3 38.141 54 32.004 45
Continued
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of 0.73 were higher than under the alternative assump-
tion of 0.65.
Regarding the shape of the model, slightly higher
estimates were obtained under the recommended
log-linear model. As for the alternative background level
of 7.5 µg/m3, lower estimates than for the recommended
background concentration of 3 µg/m3 were calculated.
Concerning mortality associated with short-term
exposure to O3, slightly higher ADs estimates than
for the suggested background level of 70 µg/m3
were obtained under the alternative background level
of 50 µg/m3 for both sets of risk coefﬁcients.
Negative estimates were also obtained as described
before.
Table 5 Continued
Linear relationship1
PM2.5/PM10 ratio: 0.73
1
Counterfactual concentration *10 µg/m3 †25 µg/m3 ‡3 µg/m3 ‡§7.5 µg/m3
PM2.5/PM10 ratio: 0.65
1 8
Lower estimate 5.468 8 −0.860 −1 8.284 12 6.484 9
Central estimate 15.204 22 −2.544 −4 22.401 32 17.848 25
Higher estimate 23.938 34 −4.256 −6 34.345 49 27.832 40
All-cause mortality and short-term exposure to O3: all ages
Counterfactual concentration *70 µg/m3 ¶50 µg/m3
Indicator AFs Ads AFs ADs
Source of risk estimates: Anderson et al 20
Lower estimate 0.356 9 0.456 12
Central estimate 1.416 36 1.809 46
Higher estimate 2.463 63 3.142 81
Source of risk estimates: HRAPIE Project 8
Lower estimate 0.994 25 1.270 33
Central estimate 2.046 52 2.611 67
Higher estimate 3.016 77 3.845 99
Respiratory mortality and short-term exposure to O3: all ages
Counterfactual concentration *70 µg/m3 ¶50 µg/m3
Indicator AFs Ads AFs ADs
Source of risk estimates: Anderson et al 20
Lower estimate −3.642 −10 −4.687 −12
Central estimate −0.717 −2 −0.918 −2
Higher estimate 2.809 7 3.582 10
Source of risk estimates: HRAPIE Project 8
Lower estimate −0.789 −2 −1.011 −3
Central estimate 2.046 5 2.611 7
Higher estimate 4.857 13 6.175 16
Cardiovascular mortality and short-term exposure to O3: all ages
Counterfactual concentration *70 µg/m3 ¶50 µg/m3
Indicator AFs ADs AFs ADs
Source of risk estimates: Anderson et al 20
Lower estimate 2.115 18 2.7 24
Central estimate 2.809 25 3.582 31
Higher estimate 3.497 31 4.455 39
Source of risk estimates: HRAPIE Project 8
Lower estimate 0.923 8 1.180 10
Central estimate 3.429 30 4.368 38
Higher estimate 5.862 51 7.443 65
Counterfactual concentration:
*Target concentration (background level for mortality and short-term exposure to O3) from WHO.
23
†Target concentration from Directive 2008/50/EC.19
‡Background level from Ostro.1
§Background level from Pope III.22
¶Background level from Amann et al.3
ADs, attributable deaths; AFs, attributable fractions; HRAPIE, Health risks of air pollution in Europe; PM, particulate matter; TADs, targeted
avoidable deaths.
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DISCUSSION
This HIA study pointed to a detrimental effect on mor-
tality from PM10, PM2.5 and O3 exposure. Our estimates
indicated a higher number of avoidable deaths from
reducing pollutant concentrations to the WHO AQG
levels than from a reduction to the European Union
(EU) standards. The impact would have been greater if
attainment of the legal standards at the moment had
not been achieved.
When negative or null estimates were obtained, no
deaths would have been possible to attribute or prevent
relative to the exposure scenarios considered.
Comparison with other studies
HIA is an underutilised tool in Spain.25 To the best of
our knowledge, there are no Spanish studies that have
followed this EBD series guideline on outdoor air
pollution.1 Estimates of the burden of disease associated
to air pollution were calculated in various Spanish cities
within the framework of different European26–28 and
Spanish29–45 projects. A study estimated the health and
economic beneﬁts resulting from two scenarios of
improved air quality (EU standards and WHO targets) in
Barcelona.46 Two recent studies estimated the number of
avoidable deaths associated with reducing PM2.5 in
Spain.47 48 The heterogeneity of exposure data and
methods used in the studies conducted in Spain do not
let compare properly their results with our estimates.
However, our estimates follow the trend showed by the
literature.
Strengths and weaknesses of this study
This type of analysis has a range of inherent uncertain-
ties and methodological limitations that must be consid-
ered when interpreting our estimates. Limitations can
affect every step of the method.1
CIs only cover statistical uncertainty related to the risk
estimates.Our estimates are sensitive to the alternative
assumptions for PM2.5/PM10 ratio, background concen-
tration and shape of CRF. Although the risk parameters
are never completely transferable from one population
to another, the methods and CRFs summarised by the
WHO applied in our study provide the most appropri-
ate, albeit imperfect, effect estimates. The methodology
described in the current EBD series can be adapted
both to local and national levels. The updated guidance
and risk coefﬁcients arising from the review process
coordinated by the WHO would provide more accurate
estimates of the impact on health that will be used to
revise our results.
Caution must be taken as short-term estimates should
not be added to long-term estimates or estimates for
children since adding them would involve double
count.1 As mentioned previously, the estimates for all-
cause mortality associated with short-term exposure to
PM10 for <5 years might result in an overestimate.
1
Probably no deaths would have been possible to attri-
bute or prevent in children <5 years old related to
short-term exposure to PM10. It should be emphasised
that the HRAPIE report indicates that generalisation of
the recommended approaches to other regions of the
globe or individual countries, or to particular mixtures
at the local level, may be not appropriate. Speciﬁcally,
risk estimates for certain health outcomes exhibit more
uncertainty. It bears noting that the background
national data on all-cause mortality have greater preci-
sion than the cause-speciﬁc data. The latter may be
affected by misclassiﬁcation of causes of death in mortal-
ity registration.8
Our estimates of mortality associated to long-term
exposure to PM2.5 show quite a large range. Reality is
likely to lie in between. Probably differences in mortality
rates and the proportion of population in age groups
affect our results. Likely a data set including a longer
period of analysis would have provided a better scope of
the real impact of PM2.5.
Regarding the ambient exposure of the population,
our results are affected by the ecological fallacy because
of using ecological data on exposure to pollutants. We
have also underestimated the effect of outdoor air pollu-
tion as morbidity adverse health effects, which impose a
considerable health burden, are not included in the
assessment. Similarly, assuming independence of the
effects of pollutants could overestimate our results.
Our data (described in table 1) are based on a network
of ﬁxed-site monitors whose location, number and range
of pollutants measured have changed over time, decreas-
ing the quality and robustness of our exposure estimates.
Equally, the effect on averages of outliers, street canyon
effect and hot spot sites can overestimate our results.
Likewise, PM10 concentration data corrected for
sub-Saharan dust intrusions were not available. In the
absence of local data on ﬁne particle matter, PM2.5 levels
were estimated from the recommended PM2.5/PM10
ratio.1 There is a lack of a municipal emission source
inventory and of local data for background levels of the
pollutants considered in our study. In addition, the
impact of other co-pollutants and seasonal effects (for
instance the strong seasonal cycle for O3, high in summer
and low in winter) can inﬂuence our estimates.
Therefore, although presenting our results with a CI can
provide a range for our estimates and set bounds to statis-
tical error, we cannot diminish the uncertainty embodied
in our results by the quality of the exposure data and our
assumptions to estimate population exposure.
Meaning of the study and directions for future research
The WHO EBD series framework seems to prove useful
to apply at local level. Our estimates, although con-
strained by major uncertainties, should be a quantitative
input to local authorities become aware of the magni-
tude of the problem, help realise the substantial poten-
tial health beneﬁts from compliance with WHO AQG
target values and prioritise actions on strengthening
control of outdoor air pollution.
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Local governments, through policies aimed mainly to
reduce emissions from urban transport that provide
alternatives to private motor vehicle trafﬁc, could
achieve considerable health gains. It must be stressed
that these strategies, through synergies between policies,
may yield other important co-beneﬁts for health in
trafﬁc injury prevention, noise reduction, creation of
spaces for exercise and recreation, etc.1 Actions should
be taken to provide the population with this kind of
information, since their awareness and active participa-
tion are basic to reduce air pollution.
As implications for future research, the recommenda-
tions and risk coefﬁcients resulting from the current evi-
dence review process led by the WHO will be used to
revise and update our estimates. Likewise, the analysis
with local measurements of PM2.5 to reduce uncertainty
of estimates related to this pollutant should also be con-
ducted. Collective efforts for developing the availability
of morbidity data are needed in order to improve the
evaluation of the burden of disease. Future research on
improving the monitoring and description of the urban
atmosphere and the background levels of pollutants in
our local and regional setting should be developed.
Conclusions
Our study suggests a not negligible impact on mortality
of outdoor air pollution by PM10, PM2.5 and O3. The
implementation of the EBD series guideline on outdoor
air pollution1 compiled by the WHO provides critical
information to distinguish an improvement range in air
pollution control.
Our results support a reﬂection on the opportunities to
develop feasible actions in order to adopt the more strin-
gent WHO targets, yielding more beneﬁts than simply
attaining the current Directive 2008/50/EC, and to
enhance the monitoring of ambient air quality at local level.
In any case, we cannot forget that small reductions in
the levels of risk factors may yield a great beneﬁt for the
health of the entire population.
Acknowledgements The authors thank Dr Annette Prüss-Üstün and Dr
Sophie Bonjour from the WHO for the provision of the spreadsheet and
valuable comments on its use, the Environmental Health Unit of the city of
Valladolid for the provision of data on air pollution. The authors would also
like to thank King Philip III of Spain for moving the capital city of Spain from
Valladolid to Madrid in 1606 facilitating unconsciously the future feasibility of
long-term air pollution control strategies.
Contributors MCA had the idea for this study from his doctoral thesis,
leading the design, exposure assessment, data analysis and drafting of the
manuscript. MFMM contributed to the exposure assessment, data analysis
and the statistical script. AAM, MAC, FCV and AAG contributed to the
exposure assessment and data analysis. All authors contributed to the critical
reading of and comments to the manuscript, interpretation of data and
approved the final draft. MCA is the guarantor.
Disclaimer The views expressed herein can in no way be taken to reflect the
official opinion of the Environmental Health Unit of the city of Valladolid.
Funding This research received no specific grant from any funding agency in
the public, commercial or not-for-profit sectors.
Competing interests None.
Provenance and peer review Not commissioned; externally peer reviewed.
Data sharing statement Extra data can be accessed via the Dryad data
repository at http://datadryad.org/ with the doi:10.5061/dryad.3p4f3.
Open Access This is an Open Access article distributed in accordance with
the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license,
which permits others to distribute, remix, adapt, build upon this work non-
commercially, and license their derivative works on different terms, provided
the original work is properly cited and the use is non-commercial. See: http://
creativecommons.org/licenses/by-nc/4.0/
REFERENCES
1. Ostro B. Outdoor air pollution: assessing the environmental burden
of disease at national and local levels. Geneva: World Health
Organization. 2004. (WHO. Environmental Burden of Disease
Series.No. 5). http://www.who.int/quantifying_ehimpacts/publications/
ebd5/en/ (accessed 12 Apr 2014).
2. Amann M, Derwent D, Forsberg B, et al. Health risks of particulate
matter from long-range transboundary air pollution. Copenhagen:
World Health Organization, Regional Office for Europe, 2006. http://
www.euro.who.int/en/health-topics/environment-and-health/air-
quality/publications/pre2009/health-risks-of-particulate-matter-from-
long-range-transboundary-air-pollution (accessed 12 Apr 2014).
3. Amann M, Derwent D, Forsberg B, et al. Health risks of ozone from
long-range transboundary air pollution. Copenhagen, World Health
Organization, Regional Office for Europe, 2008. http://www.euro.
who.int/en/publications/abstracts/health-risks-of-ozone-from-long-
range-transboundary-air-pollution (accessed 12 Apr 2014).
4. Hoek G, Krishnan RM, Beelen R, et al. Long-term air pollution exposure
and cardio- respiratory mortality: a review. Environ Health 2013;12:43.
5. Beelen R, Raaschou-Nielsen O, Stafoggia M, et al. Effects of long-
term exposure to air pollution on natural-cause mortality: an analysis
of 22 European cohorts within the multicentre ESCAPE project.
Lancet 2014;383:785–95.
6. Burnett RT, Pope CA III, Ezzati M, et al. An integrated risk function for
estimating the global burden of disease attributable to ambient fine
particulate matter exposure. Environ Health Perspect 2014;122:397–403.
7. Review of evidence on health aspects of air pollution—REVIHAAP
project. Technical report. World Health Organization 2013. http://
www.euro.who.int/en/health-topics/environment-and-health/air-
quality/activities/health-aspects-of-air-pollution-and-review-of-eu-
policies-the-revihaap-and-hrapie-projects (accessed 12 Apr 2014).
8. Health risks of air pollution in Europe—HRAPIE project.
Recommendations for concentration–response functions for cost–
benefit analysis of particulate matter, ozone and nitrogen dioxide.
World Health Organization. 2013. http://www.euro.who.int/en/health-
topics/environment-and-health/air-quality/activities/health-aspects-of-
air-pollution-and-review-of-eu-policies-the-revihaap-and-hrapie-
projects (accessed 12 Apr 2014).
9. http://www.who.int/gho/phe/outdoor_air_pollution/burden_text/en/
(accessed 12 Apr 2014).
10. http://www.iarc.fr/en/media-centre/iarcnews/pdf/pr221_E.pdf
(accessed 12 Apr 2014).
11. Prüss-Üstün A, Corvalán C. Preventing disease through healthy
environments. Towards an estimate of the environmental burden of
disease. WHO, 2006. http://www.who.int/quantifying_ehimpacts/
publications/preventingdisease/en/ (accessed 12 Apr 2014).
12. Prüss-Üstün A, Mathers C, Corvalán C, et al. Introduction and
methods: assessing the environmental burden of disease at national
and local levels. Geneva: World Health Organization, 2003. (WHO
Environmental Burden of Disease Series, No.1). http://www.who.int/
quantifying_ehimpacts/publications/9241546204/en/ (accessed 12
Apr 2014).
13. Diéguez Rodríguez JJ, Muñoz MM, Padilla Gómez L, et al. «Estudio
y evaluación de la contaminación atmosférica por ozono troposférico
en España ». 2009. Informe final. Ministerio de Medio Ambiente y
Medio Rural y Marino. http://www.magrama.gob.es/es/calidad-y-
evaluacion-ambiental/temas/atmosfera-y-calidad-del-aire/calidad-del-
aire/estudios/ (accessed 6 Aug 2014).
14. Mogo S, Cachorro VE, De Frutos, AM. Morphological, chemical and
optical absorbing characterization of aerosols in the urban
atmosphere of Valladolid. Atmos Chem Phys 2005;5:2739–48.
15. http://www10.ava.es/rccava/03contaminantes2.html (accessed 6
Aug 2014).
16. http://www10.ava.es/rccava/08biblioteca1.html (accessed 14 Dec 2013).
17. Directive1999/30/EC. http://ec.europa.eu/environment/air/quality/
legislation/existing_leg.htm (accessed 28 Feb 2014).
Cárdaba Arranz M, et al. BMJ Open 2014;4:e005999. doi:10.1136/bmjopen-2014-005999 11
Open Access
group.bmj.com on December 1, 2014 - Published by http://bmjopen.bmj.com/Downloaded from 
18. Directive 2000/69/EC. http://ec.europa.eu/environment/air/quality/
legislation/existing_leg.htm (accessed 28 Feb 2014).
19. Directive 2008/50/EC. http://ec.europa.eu/environment/air/quality/
standards.htm (accessed 28 Feb 2014).
20. Anderson HR, Atkinson RW, Peacock JL, et al. Meta-analysis of
time-series studies and panel studies of particulate matter (PM) and
ozone (O3). Report of a WHO task group. 2004. http://www.euro.
who.int/en/health-topics/environment-and-health/air-quality/
publications/pre2009/meta-analysis-of-time-series-and-panel-studies-
of-particulate-matter-and-ozone (accessed 12 Apr 2014).
21. http://www.ine.es/en/welcome.shtml (accessed 14 Dec 2013).
22. Pope CA III, Thun MJ, Namboodiri MM, et al. Particulate air pollution
as a predictor of mortality in a prospective study of US adults. Am J
Respir Crit Care Med. 1995;151:669–74.
23. WHO Air Quality Guidelines for particulate matter, ozone, nitrogen
dioxide and sulfur dioxide. Global update 2005.Summary of risk
assessment. WHO. 2006. http://www.who.int/phe/health_topics/
outdoorair/outdoorair_aqg/en/ (accessed 12 Apr 2014).
24. California Environmental Protection Agency. Air Resources Board.
Review of the California ambient air quality standard for ozone.
Volume IV of IV. Appendices B-G.Staff Report. Initial statement of
reasons for proposed rulemaking. 27 October 2005. http://www.arb.
ca.gov/carbis/research/aaqs/ozone-rs/rev-staff/vol4.pdf (accessed
12 Apr 2014).
25. Boldo E, Aragonés N, Medina S, et al. Evaluación de Impacto en
Salud: una herramienta infrautilizada en salud pública. Ejemplo
Apheis (Air Pollution and Health: a European Information System).
Bol Epidemiol Sem 2005;13:97–108. http://gesdoc.isciii.es/
gesdoccontroller?action=download&id=06/03/2013–9bf3a16ce7
(accessed 12 Apr 2014).
26. Touloumi G, Katsouyanni K, Zmirou D, et al. Short-term effects of
ambient oxidant exposure on mortality: a combined analysis within
the APHEA project. Am J Epidemiol 1997;146:177–85.
27. Katsouyanni K, Touloumi G, Samoli E, et al. Confounding and effect
modification in the short-term effects of ambient particles on total
mortality: results from 29 European cities within the APHEA 2
project. Epidemiology 2001;12:521–31.
28. Le Tertre A, Medina S, Samoli E, et al. Short-term effects of
particulate air pollution on cardiovascular diseases in eight
European cities. J Epidemiol Community Health 2002;56:773–9.
29. Ballester F, Corella D, Pérez-Hoyos S, et al. Air pollution and
mortality in Valencia, Spain: a study using the APHEA methodology.
J Epidemiol Community Health 1996;50:527–33.
30. Ballester F, Rodríguez P, Iñíguez C, et al. Air pollution and
cardiovascular admissions association in Spain: results within
the EMECAS project. J Epidemiol Community Health 2006;60:328–36.
31. Sunyer J, Antó JM, Murillo C, et al. Effects of urban air pollution on
emergency room admissions for chronic obstructive pulmonary
disease. Am J Epidemiol 1991;134:277–86.
32. Sunyer J, Basagaña X. Particles, and not gases, are associated with
the risk of death in patients with chronic obstructive pulmonary
disease. Int J Epidemiol 2001;30:1138–40.
33. Guillén Pérez JJ, Guillén Grima F, Medrano Tortosa J, et al.
Afluencia inusual por asma y enfermedad pulmonar obstructiva
crónica en urgencias hospitalarias y contaminación por SO2 en
Cartagena. Rev Esp Salud Publica 1995;69:305–14.
34. Tenías JM, Ballester F, Rivera ML. Association between hospital
emergency visits for asthma and air pollution in Valencia, Spain.
Occup Environ Med 1998;55:541–7.
35. Ballester F, Iniguez C, Pérez-Hoyos S, et al. Polución atmosférica
particulada y salud en Valencia. España. 1994–1996. Gac Sanit
2002;16:464–79.
36. Galan I, Tobías A, Banegas JR, et al. Short-term effects of air
pollution on daily asthma emergency room admissions. Eur Respir J
2003;22:802–8.
37. Sunyer J, Castellsagué J, Sáez M, et al. Air pollution and mortality in
Barcelona. J Epidemiol Community Health 1996;50(Suppl 1):
s76–80.
38. Tobías A, Sunyer J, Castellsague J, et al. Impacto de la
contaminación atmosférica sobre la mortalidad y las urgencias por
enfermedad pulmonar obstructiva crónica y asma en Barcelona. Gac
Sanit 1998;12:223–30.
39. Sunyer J, Basagana X, Belmonte J, et al. Effect of nitrogen dioxide
and ozone on the risk of dying in patients with severe asthma.
Thorax 2002;57:687–93.
40. Sunyer J, Schwartz J, Tobías A, et al. Patients with chronic
obstructive pulmonary disease are at increased risk of death
associated with urban particle air pollution: a case-crossover
analysis. Am J Epidemiol 2000;151:50–6.
41. Ballester Diez F, Sáez Zafra M, Alonso Fustel ME, et al. El proyecto
EMECAM: estudio multicéntrico español sobre la relación entre la
contaminación atmosférica y la mortalidad. Antecedentes,
participantes, objetivos y métodología. Rev Esp Salud Pública
1999;73:165–75.
42. Ballester F, Sáez M, Pérez-Hoyos S, et al. The EMECAM project:
a multicentre study on air pollution and mortality in Spain: combined
results for particulates and for sulfur dioxide. Occup Environ Med
2002;59:300–8.
43. Alonso Fustel E, Martínez Rueda T, Cambra Contín K, et al.
Evaluación en cinco ciudades españolas del impacto en salud de la
contaminación atmosférica por partículas. Proyecto europeo
APHEIS. Rev Esp Salud Publica 2005;79:297–308.
44. Boldo E, Medina S, LeTertre A, et al. Apheis: health impact
assessment of long-term exposure to PM(2.5) in 23 European cities.
Eur J Epidemiol 2006;21:449–58.
45. Ballester F, Medina S, Boldo E, et al. Reducing ambient levels of
fine particulates could substantially improve health: a mortality
impact assessment for 26 European cities. J Epidemiol Community
Health 2008;62:98–105.
46. Pérez L, Sunyer J, Künzli N. Estimating the health and economic
benefits associated with reducing air pollution in the Barcelona
metropolitan area (Spain). Gac Sanit 2009;23:287–94.
47. Boldo E, Linares C, Lumbreras J, et al. Health impact assessment of
a reduction in ambient PM2,5 levels in Spain. Environ Int
2011;37:342–8.
48. Boldo E, Linares C, Aragonés N, et al. Air quality modeling and
mortality impact of fine particles reduction policies in Spain. Environ
Res 2014;128:15–26.
12 Cárdaba Arranz M, et al. BMJ Open 2014;4:e005999. doi:10.1136/bmjopen-2014-005999
Open Access
group.bmj.com on December 1, 2014 - Published by http://bmjopen.bmj.com/Downloaded from 
Valladolid, Spain
Health impact assessment of air pollution in
Gómez
Margarita Alonso Capitán, Fernando Carreras Vaquer and Ana Almaraz 
Mario Cárdaba Arranz, María Fe Muñoz Moreno, Alicia Armentia Medina,
doi: 10.1136/bmjopen-2014-005999
2014 4: BMJ Open 
 http://bmjopen.bmj.com/content/4/10/e005999
Updated information and services can be found at: 
These include:
References
 #BIBLhttp://bmjopen.bmj.com/content/4/10/e005999
This article cites 29 articles, 13 of which you can access for free at: 
Open Access
http://creativecommons.org/licenses/by-nc/4.0/non-commercial. See: 
provided the original work is properly cited and the use is
non-commercially, and license their derivative works on different terms, 
permits others to distribute, remix, adapt, build upon this work
Commons Attribution Non Commercial (CC BY-NC 4.0) license, which 
This is an Open Access article distributed in accordance with the Creative
service
Email alerting
box at the top right corner of the online article. 
Receive free email alerts when new articles cite this article. Sign up in the
Collections
Topic Articles on similar topics can be found in the following collections 
 (845)Public health
 (879)Epidemiology
Notes
http://group.bmj.com/group/rights-licensing/permissions
To request permissions go to:
http://journals.bmj.com/cgi/reprintform
To order reprints go to:
http://group.bmj.com/subscribe/
To subscribe to BMJ go to:
group.bmj.com on December 1, 2014 - Published by http://bmjopen.bmj.com/Downloaded from 
